


# PRODUCT INFORMATION



## AMG 517

Item No. 26191

**CAS Registry No.:** 659730-32-2  
**Formal Name:** N-[4-[[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]-acetamide  
**MF:** C<sub>20</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S  
**FW:** 430.4  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 247, 272 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

AMG 517 is supplied as a crystalline solid. A stock solution may be made by dissolving the AMG 517 in the solvent of choice. AMG 517 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of AMG 517 in these solvents is approximately 3.3, 14.3, and 112.5 mg/ml, respectively.

### Description

AMG 517 is an antagonist of transient receptor potential vanilloid 1 (TRPV1; IC<sub>50</sub> = 0.9 nM).<sup>1</sup> It inhibits mechanical and thermal allodynia in a rat model of burn injury when administered intrathecally at a dose of 165 μg.<sup>2</sup> AMG 517 (150 and 300 μg/kg) also reverses increases in the level of calcitonin gene-related peptide (CGRP) and increases expression of GFAP and GAP-43 in the dorsal horn of the spinal cord, as well as enhances axonal regeneration in a rat model of sciatic nerve transection injury.<sup>3</sup>

### References

1. Blum, C.A., Caldwell, T., Zheng, X., *et al.* Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists. *J. Med. Chem.* **53**(8), 3330-3348 (2010).
2. Green, D.P., Ruparel, S., Gao, X., *et al.* Central activation of TRPV1 and TRPA1 by novel endogenous agonists contributes to mechanical allodynia and thermal hyperalgesia after burn injury. *Mol. Pain* **12**, (2016).
3. Bai, J., Liu, F., Wu, L.-F., *et al.* Attenuation of TRPV1 by AMG-517 after nerve injury promotes peripheral axonal regeneration in rats. *Mol. Pain* **14**, 1-10 (2018).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/20/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM